Cocrystal Joins Russell Microcap® Index
June 28, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 28, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
June 23, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants
June 14, 2021 08:30 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
June 09, 2021 14:30 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces the Passing of Chairman, CEO and Co-founder Dr. Gary Wilcox
May 28, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 28, 2021 (GLOBE NEWSWIRE) -- With great sadness, Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”) announces that Gary Wilcox, Ph.D., Chairman, CEO and...
Cocrystal Pharma Reports First Quarter 2021 Financial Results and Provides Business Update
May 17, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 17, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces Closing of $40 Million Bought Deal
May 07, 2021 16:05 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 07, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
May 04, 2021 18:41 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 04, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Provides Update on its COVID-19 Antiviral Discovery and Development Programs
May 03, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., May 03, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones
March 17, 2021 08:30 ET
|
Cocrystal Pharma, Inc.
Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs Ends 2020 with cash exceeding $33 million and a clean capital structure BOTHELL, Wash., March...